International Journal of Bipolar Disorders
August 13, 2022
A. Nierenberg, P. Lavin, Daniel C Javitt et al.
Background We tested the hypothesis that, after initial improvement with intravenous ketamine in patients with bipolar disorder (BD) with severe depression and acute suicidal thinking or behavior, a fixed-dose combination of oral D-cycloserine (DCS) and lurasidone (NRX-101) can maintain improvement more effectively than lurasidone alone. Methods This was a multi-center, double-blind, twostage,...
bioRxiv Preprint Server
August 12, 2022
Daniel C Javitt, Jonathan C. Javitt
preprint
OBJECTIVE N-methyl D-aspartate Receptor (NMDAR) antagonist antidepressants have known potential for abuse liability. The aim of this study was to evaluate the abuse liability of D-cycloserine (DCS), using a self-administration paradigm in which DCS was tested in its efficacy in substituting for ketamine in ketamine-dependent rats.
Schizophrenia Bulletin
September 2012
Daniel C Javitt
At present, all medications for schizophrenia function primarily by blocking dopamine D2 receptors. Over 50 years ago, the first observations were made that subsequently led to development of alternative, glutamatergic conceptualizations. This special issue traces the historic development of the phencyclidine (PCP) model of schizophrenia from the initial description of the psychotomimetic...
Schizophrenia Bulletin
September 1, 2012
Daniel C Javitt, Stephen R Zukin, Uriel Heresco-Levy et al.
Over the last 20 years, glutamatergic models of schizophrenia have become increasingly accepted as etiopathological models of schizophrenia, based on the observation that phencyclidine (PCP) induces a schizophrenia-like psychosis by blocking neurotransmission at N-methyl-D-aspartate (NMDA)-type glutamate receptors. This article reviews developments in two key predictions of the model: first,...
Clinical schizophrenia & related psychoses
October 1, 2010
Joshua T. Kantrowitz, Daniel C Javitt
Clinical concepts of mental illness have always been modulated by underlying theoretical considerations. For the past fifty years, schizophrenia has been considered primarily a disease of dopaminergic neurotransmission. Although this conceptualization has helped greatly in explaining the clinical effects of psychostimulants and guiding the clinical use of both typical and atypical...
Novartis Foundation symposium
2008
Daniel C Javitt
Schizophrenia is a serious mental disorder that affects up to 1% of the population worldwide. Traditional models of schizophrenia have emphasized dopaminergic dysfunction. Over the last 15 years, however, glutamatergic models have become increasingly mainstream, and account for features of the disorder that are poorly explained by dopaminergic dysfunction alone. Glutamatergic models, such as...
Psychopharmacology
May 1, 2007
Gary S Linn, Robert T O'Keeffe, Kenneth Lifshitz et al.
Schizophrenia is a major mental disorder. Dissociative anesthetics such as phencyclidine (PCP) produce a syndrome in humans that is clinically indistinguishable from schizophrenia by blocking neurotransmission at N-methyl-D-aspartate (NMDA)-type glutamate receptors. NMDA receptors in brain are modulated by the amino acid glycine (GLY), which reverses neurochemical and behavioral effects of PCP...
International review of neurobiology
2007
Daniel C Javitt
Schizophrenia is a serious mental disorder that affects up to 1% of the population worldwide. As of yet, neurochemical mechanisms underlying schizophrenia remain unknown. To date, the most widely considered neurochemical hypothesis of schizophrenia is the dopamine hypothesis, which postulates that symptoms of schizophrenia may result from excess dopaminergic neurotransmission particularly in...
Neuropsychopharmacology
2003
Andrea Balla, Henry Sershen, Michael Serra et al.
Functional dopaminergic hyperactivity is a key feature of schizophrenia. Etiology of this dopaminergic hyperactivity, however, is unknown. We have recently demonstrated that subchronic phencyclidine (PCP) treatment in rodents induces striatal dopaminergic hyperactivity similar to that observed in schizophrenia. The present study investigates the ability of PCP to potentiate amphetamine-induced...
Archives of General Psychiatry
December 1, 2000
Daniel Umbricht, Liselotte Schmid, Rene Koller et al.
590 citations
BACKGROUND: In patients with schizophrenia, deficient generation of mismatch negativity (MMN)-an event-related potential (ERP) indexing auditory sensory ("echoic") memory-and a selective increase of "context dependent" ("BX") errors in the "A-X" version of the Continuous Performance Test (AX-CPT) indicate an impaired ability to form and use transient memory traces. Animal and human studies...
Psychiatric Annals
March 1, 1993
Uriel Heresco-Levy, Daniel C Javitt, Stephen R Zukin
The hyperdopaminergic theory of schizophrenia cannot account for many dimensions of the illness.
Andrew C Murphy, Antigona Martinez, Yadi Chen et al.
Abstract: Background: Auditory verbal hallucinations (AVH) are among the most disabling symptoms of schizophrenia, yet the network-level mechanisms linking auditory dysfunction to hallucination severity remain poorly characterized, limiting targeted therapeutic development. Methods: Using resting-state fMRI and high-resolution surface-based parcellation (HCP-MMP), we examined auditory-language...